https://doi.org/10.55788/07799c07
Prof. Namasivayam Ambalavanan (University of Alabama, AL, USA) introduced the rationale for the study by stating that BPD is a prevalent complication after an extremely preterm birth (<30 weeks gestation), which may partially be attributable to inflammation as a result of mechanical ventilation. It is unknown whether hydrocortisone treatment after the first postnatal week might be able to improve survival without BPD [1]. To that end, researchers determined the efficacy of hydrocortisone in facilitating extubation, thereby increasing survival without moderate or severe BPD, by initiating the Hydrocortisone and Extubation study (NCT01353313). The study was also recently published in the New England Journal of Medicine [2].
Infants (n=800) with a gestational age <30 weeks (mean birth weight 715Ā±167 g; mean gestational age 24.9Ā±1.5 weeks) who had been intubated for at least 7 days at 14 to 28 days of life were randomised to receive either hydrocortisone (4 mg/kg body weight/day tapered over 10 days) or placebo. The primary efficacy endpoint was the use of respiratory support at 36 weeks postmenstrual age or survival without moderate or severe BPD. The primary safety endpoint was survival without moderate or severe neurodevelopmental impairment at 22ā26 months adjusted age.
At 36 weeks, survival without BPD was reported in 66 of 398 infants (16.6%) in the hydrocortisone arm and in 53 of 402 (13.2%) in the placebo arm (adjusted rate ratio 1.27; 95% CI 0.93ā1.74; not significant). For the safety endpoint, there was also no difference observed at 2 years follow-up; survival without moderate or severe neurodevelopmental impairment occurred in 36.9% in the hydrocortisone arm and in 37.3% in the placebo arm (adjusted rate ratio 0.98; 95% CI 0.81ā1.18; not significant). Furthermore, although most adverse events occurred at similar rates in both groups, hypertension requiring treatment was more common in the hydrocortisone arm than in the placebo arm (4.3% vs 1.0%).
Enrolled children are being seen at 5ā6 years for further follow-up.
- Ambalavanan N, et al. The effect of hydrocortisone on survival without BPD at 36 weeks and on neurodevelopmental impairment (NDI) at 2 years in intubated infants born <30 weeks GA. Session A2, ATS International Conference 2022, San Francisco, CA, USA, 13ā18 May.
- Watterberg KL, et al. N Engl J Med 2022;386(12):1121ā1131.
Copyright Ā©2022 Medicom Medical Publishers
Posted on
Previous Article
« CPAP temporarily supports pulmonary oxygenation in morbidly obese patients Next Article
Novel PDE4B inhibitor offers breakthrough for IPF »
« CPAP temporarily supports pulmonary oxygenation in morbidly obese patients Next Article
Novel PDE4B inhibitor offers breakthrough for IPF »
Table of Contents: ATS 2022
Featured articles
Letter from the Editor
COVID-19
Nebulised aviptadil āfutileā in I-SPY COVID-19 trial
Lung transplantation after COVID-19-associated ARDS
Mesenchymal stem cells offer no benefit in COVID-19
Alpha-1 antitrypsin for ARDS secondary to severe COVID-19
Frailty prevalent 5 months following hospitalisation for COVID-19
Paediatric long COVID lacks definitions
Asthma Clinical Trial Updates
MANDALA and DENALI pattern success for albuterol-budesonide in asthma
ACOUSTICS data sounds good for adolescent asthma exacerbations
Type 2 asthma in children managed by dupilumab, despite atopic comorbidities
NAVIGATOR steers asthma patients to tezepelumab
High-intensity interval training slashes daily corticosteroids in asthma
Chronic Obstructive Pulmonary Disease
Threeās a crowd for triple therapy in COPD
Higher 1-year COPD mortality after hospitalisation for White patients
Reducing dyspnoea in chronic lung disease through weight loss
CT-evident mucus plugs in COPD associated with death
Home-based rehabilitation improves COPD: a randomised study
Highlighted Advances
Novel P2X3 antagonist can SOOTHE chronic cough
Colistimethate sodium PROMISing for non-cystic fibrosis bronchiectasis
Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?
PAGANINI phase 2b data promising for eliapixant
POISE-3: Tranexamic acid for non-cardiac surgery
Obstructive sleep apnoea in most children with pulmonary hypertension
No screening evidence for COPD
Novel PDE4B inhibitor offers breakthrough for IPF
Hydrocortisone does not help preterm infants
CPAP temporarily supports pulmonary oxygenation in morbidly obese patients
ISAACC trial: CPAP controls blood pressure in ACS patients with severe OSA
Related Articles
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com